Lord, Abbett & Co. LLC Allogene Therapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 09, 2021	SELL	$25.24 - $43.45 $11.4 Million - $19.6 Million	-450,863 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$32.38 - $44.96 $14.6 Million - $20.3 Million	450,863 New	450,863 $17 Million
Q4 2019 Feb 14, 2020	SELL	$24.82 - $31.4 $8.31 Million - $10.5 Million	-334,964 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $1.16 Million - $1.47 Million	-44,567 Reduced 11.74%	334,964 $9.13 Million
Q2 2019 Aug 14, 2019	BUY	$25.56 - $31.09 $41,279 - $50,210	1,615 Added 0.43%	379,531 $10.2 Million
Q1 2019 May 15, 2019	SELL	$24.82 - $32.54 $597,814 - $783,758	-24,086 Reduced 5.99%	377,916 $10.9 Million
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $9.05 Million - $13.4 Million	402,002 New	402,002 $10.8 Million

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $262M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.